| __timestamp | Amphastar Pharmaceuticals, Inc. | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 1802274 |
| Thursday, January 1, 2015 | 46974000 | 2512761 |
| Friday, January 1, 2016 | 47298000 | 2894488 |
| Sunday, January 1, 2017 | 50918000 | 8096274 |
| Monday, January 1, 2018 | 58044000 | 7985229 |
| Tuesday, January 1, 2019 | 63109000 | 8994597 |
| Wednesday, January 1, 2020 | 65157000 | 29772000 |
| Friday, January 1, 2021 | 68920000 | 33907000 |
| Saturday, January 1, 2022 | 66592000 | 26579000 |
| Sunday, January 1, 2023 | 80393000 | 49868547 |
Data in motion
In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and Amphastar Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Amphastar Pharmaceuticals consistently outpaced Verona Pharma in SG&A spending, with an average annual expense of approximately $58.8 million, peaking at $80.4 million in 2023. In contrast, Verona Pharma's SG&A expenses grew significantly, from a modest $1.8 million in 2014 to nearly $49.9 million in 2023, marking a staggering increase of over 2600%. This trend highlights Verona Pharma's aggressive expansion and investment in administrative capabilities. Such financial insights are pivotal for investors and stakeholders aiming to gauge the strategic priorities and operational scale of these pharmaceutical giants.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Who Optimizes SG&A Costs Better? AbbVie Inc. or Verona Pharma plc
SG&A Efficiency Analysis: Comparing Novartis AG and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Verona Pharma plc and ADMA Biologics, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: Vericel Corporation vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.